Yorktown Management & Research Co Inc Purchases New Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Yorktown Management & Research Co Inc bought a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 4,600 shares of the biotechnology company’s stock, valued at approximately $559,000.

A number of other large investors have also bought and sold shares of the company. Janus Henderson Group PLC raised its stake in shares of Sarepta Therapeutics by 14.2% in the third quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock valued at $544,408,000 after buying an additional 543,143 shares during the period. Wellington Management Group LLP grew its position in shares of Sarepta Therapeutics by 32.3% in the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock valued at $340,527,000 after purchasing an additional 665,087 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Sarepta Therapeutics by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock valued at $211,910,000 after purchasing an additional 44,306 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its position in shares of Sarepta Therapeutics by 9.2% in the third quarter. Jacobs Levy Equity Management Inc. now owns 753,845 shares of the biotechnology company’s stock valued at $94,148,000 after purchasing an additional 63,437 shares in the last quarter. Finally, Erste Asset Management GmbH purchased a new position in shares of Sarepta Therapeutics in the third quarter valued at $79,425,000. 86.68% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the transaction, the director now owns 22,840 shares of the company’s stock, valued at $2,851,345.60. This represents a 31.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Kathryn Jean Boor sold 1,636 shares of the company’s stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the transaction, the director now directly owns 5,880 shares of the company’s stock, valued at $738,234. The trade was a 21.77 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by corporate insiders.

Sarepta Therapeutics Trading Up 0.2 %

SRPT opened at $114.08 on Wednesday. The business has a 50 day simple moving average of $122.45 and a two-hundred day simple moving average of $126.50. The firm has a market capitalization of $10.90 billion, a price-to-earnings ratio of 91.26 and a beta of 0.75. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. Sarepta Therapeutics, Inc. has a one year low of $102.15 and a one year high of $173.25.

Analyst Ratings Changes

Several equities analysts have recently weighed in on SRPT shares. HC Wainwright reiterated a “sell” rating and issued a $75.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, January 30th. Evercore ISI reduced their price target on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Needham & Company LLC restated a “buy” rating and set a $202.00 target price on shares of Sarepta Therapeutics in a research report on Monday, January 27th. Guggenheim boosted their target price on Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Finally, Piper Sandler reduced their target price on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research report on Wednesday, November 27th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Sarepta Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $178.71.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.